New GERD drug fexuprazan tested against standard treatment in 145 patients
NCT ID NCT07326904
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether fexuprazan, a new drug, can relieve heartburn and acid reflux as well as the commonly used esomeprazole. 145 adults with GERD took either fexuprazan or esomeprazole once daily for 4 weeks, with an option to continue for another 4 weeks if symptoms didn't improve. Researchers measured symptom relief using a standard questionnaire and monitored safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fexuprazan
- What this could lead to
- If fexuprazan works as well as esomeprazole, it could offer another treatment option for people with GERD to ease heartburn and acid reflux.
- What could go wrong
- This is a completed phase 3 trial, but results are not yet published. It only included 145 adults aged 18-60, so findings may not apply to older people or those with severe GERD.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-OESOPHAGEAL REFLUX DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Islam Cempaka Putih Jakarta Hospital
Jakarta Pusat, DKI Jakarta, 10510, Indonesia
-
Menteng Mitra Afia Jakarta Hospital
Jakarta Pusat, DKI Jakarta, 10340, Indonesia
-
University of Indonesia Hospital
Depok, West Java, 16424, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.